Mirador Biomedical Inc.
Reducing risk in central venous access
This article was originally published in Start Up
During insertion of central venous catheters, physicians may unintentionally advance into an artery rather than the desired vein, an error that can cause serious complications, even death. Mirador Biomedical Inc. aims to improve the safety of central venous access with its Compass platform, battery-powered, pressure-measurement devices that can rapidly detect the difference in pressures between arteries and veins.
You may also be interested in...
Medtronic is dropping plans to acquire EOFlow, which has faced numerous patent lawsuits from Insulet.
The FDA is set to make a decision on elafibranor for primary biliary cholangitis by June next year, which could give Ipsen a head start over CymaBay's seladelpar.
Earlier dialogues would mean faster access to new medicines.